Navigation Links
Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
Date:1/30/2009

- Tepnel Brings Gen-Probe Current and Future Growth Opportunities in Transplant Diagnostics and Genetic Testing, Accelerates European Expansion Strategy -

SAN DIEGO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO), a pioneer and leader in nucleic acid diagnostics for human disease, announced today that it has offered to acquire all the outstanding and to-be-issued shares of Tepnel Life Sciences, PLC (AIM: TED), a rapidly growing molecular diagnostics company based in the United Kingdom, for 27.1 pence ($0.386)(1) per share in cash, or approximately 92.8 million Pounds ($132.2 million) in total.

Both companies' boards of directors have unanimously approved the transaction, full details of which are contained in an announcement made today in the United Kingdom under Rule 2.5 of the U.K. Takeover Code.

"We believe our acquisition of Tepnel will provide immediate access to attractive growth opportunities in transplant diagnostics, genetic testing and pharmaceutical services, as well as accelerate our ongoing strategic efforts to strengthen our marketing and sales, distribution and manufacturing capabilities in the rapidly growing European molecular diagnostics market," said Hank Nordhoff, Gen-Probe's chairman and chief executive officer. "We look forward to working with the employees and customers of Tepnel to broaden the use of their innovative technologies and amplify their many successes to date."

Tepnel's board of directors intends to recommend that its shareholders approve the transaction, which is expected to close in the second quarter of 2009. Already, directors and institutional investors holding approximately 40% of Tepnel's outstanding shares have pledged to vote in favor of the transaction, which will be structured as a "scheme of arrangement" under English
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
2. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
3. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
4. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
5. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
6. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
7. Gen-Probe to Webcast Two Upcoming Investor Presentations
8. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
9. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
11. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order ... with autism, Little City took a proactive stance and began planning the Children’s Village ... grant provides valuable support to building the third home. , “We are very pleased ...
(Date:7/29/2015)... ... 29, 2015 , ... Attorneys representing American families in national talcum powder lawsuits ... now features a page dedicated to news related to pending talcum powder lawsuits, as ... Powder Lawsuit News page was launched with eight initial articles. , “We decided ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Since the late 1970s, Dr. Cottrell has been making predictions about the economy, ... Earth, documents many of these prognostications. He warns that extreme weather conditions and ...
(Date:7/29/2015)... , ... July 29, 2015 , ... " mybody ” ... look at small, medium and large businesses making an impact in their industry. Andrew ... with viewers how these advanced probiotic skincare products are designed to strengthen the skin’s ...
(Date:7/29/2015)... Charlotte, North Carolina (PRWEB) , ... July 29, ... ... that MetLife, Inc ., a global provider of life insurance, annuities, employee ... Adventure Team Challenge North Carolina inclusive sporting event taking place in Charlotte, ...
Breaking Medicine News(10 mins):Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3
... Maureen Salamon HealthDay Reporter , THURSDAY, April 28 ... in her early forties when she developed anorexia nervosa, and ... the middle of a disorder like that, you don,t know ... said. Luckily, Hodgin sought the care of a therapist ...
... arthritis may find themselves taking on a more active role ... an ongoing relationship with a primary healthcare (PHC) provider, according ... current issue of Medical Care , the study is ... a regular primary healthcare provider and patient activation, a growing ...
... MD The Association for Research in Vision and ... of distinguished fellows. The title of Fellow of ARVO ... to the Association. By accepting this honor, ARVO ... models and mentors for individuals pursuing careers in vision ...
... Association for Research in Vision and Ophthalmology (ARVO) is pleased ... will be acknowledged at the ARVO 2011 Annual Meeting, May ... Medal: Robert E. Anderson, MD, PhD, FARVO, Mildred Weisenfeld Award ... FEBOpht, FARVO, Friedenwald Award: James T. Rosenbaum, MD, FARVO, Cogan ...
... during proton treatments for pediatric cancer patients provides for ... radiation compared to standard diagnostic X-rays and cone beam ... Cancer Imaging and Radiation Therapy Symposium in Atlanta. The ... Oncology (ASTRO) and the Radiological Society of North America ...
... with fluorodeoxyglucose positron emission tomography (FDG-PET) images results ... different treatment options in head and neck cancer ... research presented today, at the Cancer Imaging and ... co-sponsored by the American Society for Radiation Oncology ...
Cached Medicine News:Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3Health News:Ongoing relationship with care provider key for patients with a chronic condition: UBC study 2Health News:2011 ARVO Fellows announced 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3Health News:Proton imaging provides more accuracy, less radiation to pediatric cancer patients 2
(Date:7/29/2015)... , July 29, 2015  Cepheid (Nasdaq: ... an update to Xpert® Carba-R, with the addition ... OXA-232.  The on-demand, molecular test also detects and ... carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and ... as CROs or Superbugs, are a growing and ...
(Date:7/29/2015)... , July 29, 2015  Mylan N.V. (NASDAQ: ... clearance from the European Commission under the European Union ... Company plc (NYSE: PRGO ; TASE).  ... commented, "Today marks yet another important milestone in the ... as further affirmation of the sound industrial logic of ...
(Date:7/29/2015)... , July 29, 2015  Efforts to improve working ... of pharmaceutical firms in North America ... is that an effective working capital management will ease ... patent cliffs. Big pharma companies expect to invest in ... Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... Satellite Symposium -, SOUTH SAN FRANCISCO, Calif., ... ), a biopharmaceutical company focused,on oncology, today announced ... prostate cancer patients from its Phase 1 study ... 2008 Genitourinary (GU) Cancers,Symposium, a meeting of the ...
... a landmark study,electronically published today in the American ... test for detecting TB infection,QuantiFERON(R)-TB Gold (QFT(TM)), has ... the conventional tuberculin skin test (TST) at predicting,which ... TB,disease. This study has important implications for the ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 2Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 3Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 4Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 5Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 2Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 3Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 4
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
... is light weight state-of-the-art precision ... design is adaptable to a ... Classic Stepper features a secure ... clockwise and counter-clockwise rotation with ...
Simply squeeze the trigger for free motion in any direction, guide the probe to the desired position, and release the trigger to hold it in place....
Floor stand stabilizer system...
Medicine Products: